Collection's Items (Sorted by Submit Date in Descending order): 1 to 20 of 41
| Publication Date | Title | Author(s) |
| Dec-2024 | Synthèse des données probantes vivantes 23.1 : Efficacité de la prophylaxie préexposition et post-exposition au moyen de la doxycycline pour la prévention des ITS bactériennes chez les populations touchées de manière disproportionnée par les infections transmissibles sexuellement | Velez, CM; Wilson, MG; Woodward, K; Presseau, J; Lavis, JN |
| Mar-2025 | Living evidence synthesis 25.2: Effectiveness of trivalent and quadrivalent influenza vaccines in preventing infection, hospitalization, and severe outcomes in the 2023–2024 season onwards | Wu, N; Phelps, A; Bain, T; Bhuiya, AR; Dass, R; Sivanesanathan, T; Whitelaw, H; Wilson, MG |
| Nov-2024 | Living evidence synthesis 25.1: Effectiveness of trivalent and quadrivalent influenza vaccines in preventing infection, hospitalization, and severe outcomes in the 2023–2024 season onwards | Wu, N; Bain, T; Bhuiya, AR; Phelps, A; Dass, R; Sivanesanathan, T; Wilson, MG |
| Dec-2024 | Living evidence synthesis 23.1: Effectiveness of doxycycline pre-exposure and postexposure prophylaxis for the prevention of bacterial STI for populations disproportionately impacted by sexually transmitted infections | Velez, CM; Wilson, MG; Woodward, K; Presseau, J; Lavis, JN |
| Apr-2024 | Living evidence synthesis 22.1: Impact of strategies to mitigate health-related misinformation in diverse settings and populations | Velez, CM; Wilson, MG; Patiño-Lugo, DF; Cura, J; Smith, M; Brehaut, J; Gretton, J; Nicklin, W; Lavis, JN |
| Mar-2024 | Living evidence synthesis 14.2: Effectiveness of masking in community and healthcare settings for reducing the incidence, transmission, hospitalizations, and deaths from respiratory infectious diseases | Velez, CM; Wilson, MG; Lavis, JN |
| Mar-2023 | COVID-19 living evidence synthesis #8 (version 22): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, J; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| Feb-2023 | COVID-19 living evidence synthesis #8 (version 21): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| Jan-2022 | COVID-19 living evidence synthesis #8 (version 2): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| Dec-2022 | COVID-19 living evidence synthesis #8 (version 19): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| Nov-2022 | COVID-19 living evidence synthesis #8 (version 18): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| Oct-2022 | COVID-19 living evidence synthesis #8 (version 17): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| Sep-2022 | COVID-19 living evidence synthesis #8 (version 16): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| Aug-2022 | COVID-19 living evidence synthesis #8 (version 15): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| Jun-2022 | COVID-19 living evidence synthesis #8 (version 14): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| Jun-2022 | COVID-19 living evidence synthesis #8 (version 13): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| May-2022 | COVID-19 living evidence synthesis #8 (version 12): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, JN; Patiño-Lugo, DF |
| May-2022 | COVID-19 living evidence synthesis #8 (version 11): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, J; Patiño-Lugo, DF |
| Dec-2021 | COVID-19 living evidence synthesis #8 (version 1): What is the effectiveness of available COVID-19 vaccines in children and adolescents in general and specifically for variants of concern? | Flórez, ID; Velásquez-Salazar, P; Martínez, JC; Linkins, L; Abdelkader, W; Iorio, A; Lavis, J; Patiño-Lugo, DF |
| Sep-2022 | COVID-19 living evidence synthesis #6 (version 6.41): What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern? | Iorio, A; Little, J; Linkins, L; Abdelkader, W; Bennett, D; Lavis, JN |
Collection's Items (Sorted by Submit Date in Descending order): 1 to 20 of 41
